Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04704661CT.gov Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Salivary Gland Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ceralasertib (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Pembrolizumab | VM Oncology, LLC | P2 | B |
| Anti-Her2 Antibody-Drug Conjugate A166 | Klus Pharma Inc. | P1/2 | CCC |
| Benzoic Acid, 4-((4-Amino-3-(4-Cyclohexyl-1-Piperazinyl)-9,10-Dihydro-9,10-Dioxo-1-Anthracenyl)Amino)- | VM Oncology, LLC | P1/2 | CCC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CC |
| Sargramostim | National Cancer Institute (NCI) | P1 | CC |
| Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific | Xencor, Inc. | P1 | CC |
| Recombinant Fowlpox-Gm-Csf | National Cancer Institute (NCI) | P1 | CC |
| Cetuximab | National Cancer Institute (NCI) | P1 | CC |
+5 more in the Salivary Gland Carcinoma cohort
Other indications for Ceralasertib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
| Breast Carcinoma | — | P2 | B · 60 |
| Breast Cancer | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ceralasertib in Salivary Gland Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ceralasertib-salivary-gland-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →